Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022

• Published in: MMWR. Morbidity and mortality weekly report 2022-11, Vol.71 (45), p.1436-1441
• Main Authors: Rosenblum, Hannah G, Wallace, Megan, Godfrey, Monica, Roper, Lauren E, Hall, Elisha, Fleming-Dutra, Katherine E, Link-Gelles, Ruth, Pilishvili, Tamara, Williams, Jennifer, Moulia, Danielle L, Brooks, Oliver, Talbot, H Keipp, Lee, Grace M, Bell, Beth P, Daley, Matthew F, Meyer, Sarah, Oliver, Sara E, Twentyman, Evelyn
• Format: Article
• Language: English
• Subjects: Advisory Committees; Antibodies; BNT162 Vaccine; Clinical trials; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Emergency medical care; FDA approval; Glycoproteins; Health surveillance; Hospitalization; Humans; Immunization; Infections; mRNA; Myocarditis; Pediatrics; Public health; RNA; RNA, Messenger; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Teenagers; United States - epidemiology; Vaccination; Vaccines; Young adults
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/MMWR.MM7145A2

Four COVID-19 vaccines are currently approved for primary series vaccination in the United States under a Biologics License Application or authorized under an emergency use authorization (EUA) by the Food and Drug Administration (FDA), and recommended for primary series vaccination by the Advisory Committee on Immunization Practices (ACIP): 1) the 2- or 3-dose monovalent mRNA BNT162b2 (Pfizer-BioNTech, Comirnaty) COVID-19 vaccine; 2) the 2- or 3-dose monovalent mRNA mRNA-1273 (Moderna, Spikevax) COVID-19 vaccine; 3) the single-dose adenovirus vector-based Ad26.COV.S (Janssen [Johnson & Johnson]) COVID-19 vaccine; and 4) the 2-dose adjuvanted, protein subunit-based NVX-CoV2373 (Novavax) COVID-19 vaccine. The number of doses recommended is based on recipient age and immunocompromise status (1). For additional protection, FDA has amended EUAs to allow for COVID-19 booster doses in eligible persons (1). Because COVID-19 vaccines have demonstrated decreased effectiveness during the period when the Omicron variant (B.1.1.529) of SARS-CoV-2 predominated, bivalent booster doses (i.e., vaccine with equal components from the ancestral and Omicron strains) were considered for the express purpose of improving protection conferred by COVID-19 vaccine booster doses (2). During September-October 2022, FDA authorized bivalent mRNA vaccines for use as a booster dose in persons aged ≥5 years who completed any FDA-approved or FDA-authorized primary series and removed EUAs for monovalent COVID-19 booster doses (1). Pfizer-BioNTech and Moderna bivalent booster vaccines each contain equal amounts of spike mRNA from the ancestral and Omicron BA.4/BA.5 strains. After the EUA amendments, ACIP and CDC recommended that all persons aged ≥5 years receive 1 bivalent mRNA booster dose ≥2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or monovalent booster doses.